Magnoflorine inhibits cisplatin-induced protective autophagy by down-regulating HMGB1 and increases drug sensitivity in drug-resistant ovarian cancer cells

IF 0.5 4区医学 Q4 OBSTETRICS & GYNECOLOGY

European journal of gynaecological oncology Pub Date : 2024-01-01 DOI:10.22514/ejgo.2024.018

Shujun Zhang, Xin He, Lei Fan, Qianru Zhang, B Gloss, K Moran-Jones, V Lin, M Gonzalez, J Scurry, N Hacker, B Pickwell-Smith, S Greenley, M Lind, U Macleod, Y Ma, Z Wei, R Bast, Z Wang, Y Li, M Gao, H He, Y Feng, L Zang, W Liu, L Ding, L Chen, J He, G Zhang, Q Pang, C Yu, J Xiong, J Zhu, J Tan, X Jiang, G Yin, L He, J Liu, Z Long, T Ghezelayagh, E Wu, E Barber, M Dao, E Zsiros, R Urban, C Chen, L Dai, M Wang, X Lai, J Wang, J Zhu, S Lin, X Zou, X Chen, Y Liu, X Yang, E Okon, W Kukula-Koch, M Halasa, A Jarzab, M Baran, M Dmoszynska-Graniczka, A Yadav, A Singh, J Phogat, A Dahuja, R Dabur, X Sun, X Zhang, H Zhai, D Zhang, S Ma, T Wei, X Xiaojun, C Peilong, T Xu, L Jiang, Z Wang, A Burges, B Schmalfeldt, L Zhong, Y Qin, M Liu, J Sun, H Tang, Y Zeng, L Wang, P Li, Y Zhou, R Gu, G Lu, C Zhang, L Zhang, Y Liu, X Lei, X Liu, H Sun, S Liu, Y Zhou, T Liu, Q Wu, H Wang, Y Sun, M Baran, P Miziak, K Bonio

{"title":"Magnoflorine inhibits cisplatin-induced protective autophagy by down-regulating HMGB1 and increases drug sensitivity in drug-resistant ovarian cancer cells","authors":"Shujun Zhang, Xin He, Lei Fan, Qianru Zhang, B Gloss, K Moran-Jones, V Lin, M Gonzalez, J Scurry, N Hacker, B Pickwell-Smith, S Greenley, M Lind, U Macleod, Y Ma, Z Wei, R Bast, Z Wang, Y Li, M Gao, H He, Y Feng, L Zang, W Liu, L Ding, L Chen, J He, G Zhang, Q Pang, C Yu, J Xiong, J Zhu, J Tan, X Jiang, G Yin, L He, J Liu, Z Long, T Ghezelayagh, E Wu, E Barber, M Dao, E Zsiros, R Urban, C Chen, L Dai, M Wang, X Lai, J Wang, J Zhu, S Lin, X Zou, X Chen, Y Liu, X Yang, E Okon, W Kukula-Koch, M Halasa, A Jarzab, M Baran, M Dmoszynska-Graniczka, A Yadav, A Singh, J Phogat, A Dahuja, R Dabur, X Sun, X Zhang, H Zhai, D Zhang, S Ma, T Wei, X Xiaojun, C Peilong, T Xu, L Jiang, Z Wang, A Burges, B Schmalfeldt, L Zhong, Y Qin, M Liu, J Sun, H Tang, Y Zeng, L Wang, P Li, Y Zhou, R Gu, G Lu, C Zhang, L Zhang, Y Liu, X Lei, X Liu, H Sun, S Liu, Y Zhou, T Liu, Q Wu, H Wang, Y Sun, M Baran, P Miziak, K Bonio","doi":"10.22514/ejgo.2024.018","DOIUrl":null,"url":null,"abstract":"Ovarian cancer (OC) is a prevalent type of gynecologic malignancy, and to improve its treatment effectiveness, it is essential to identify new and more potent therapeutic drugs. Magnoflorine is a fundamental chlorine alkaloid with various pharmacological properties, including anti-diabetic and anti-inflammatory effects. However, whether Magnoflorine can inhibit the protective autophagy induced by cisplatin by modulating (high-mobility group B1) HMGB1 requires further investigation. This study aims to assess the impact of Magnoflorine on cisplatin resistance in OC. Our findings demonstrate that Magnoflorine enhances the sensitivity of OC cells to cisplatin. Additionally, it promotes apoptosis in cisplatin-resistant OC cells and simultaneously inhibits cisplatin-induced protective autophagy. Mechanistically, Magnoflorine reduces HMGB1 expression in cisplatin-resistant OC cells. Collectively, these results suggest that Magnoflorine has potential as a therapeutic agent for cisplatin-resistant OC in future clinical applications.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"45 1","pages":"132-132"},"PeriodicalIF":0.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://oss.ejgo.net/files/article/20240206-285/pdf/EJGO2023100701.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.22514/ejgo.2024.018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Ovarian cancer (OC) is a prevalent type of gynecologic malignancy, and to improve its treatment effectiveness, it is essential to identify new and more potent therapeutic drugs. Magnoflorine is a fundamental chlorine alkaloid with various pharmacological properties, including anti-diabetic and anti-inflammatory effects. However, whether Magnoflorine can inhibit the protective autophagy induced by cisplatin by modulating (high-mobility group B1) HMGB1 requires further investigation. This study aims to assess the impact of Magnoflorine on cisplatin resistance in OC. Our findings demonstrate that Magnoflorine enhances the sensitivity of OC cells to cisplatin. Additionally, it promotes apoptosis in cisplatin-resistant OC cells and simultaneously inhibits cisplatin-induced protective autophagy. Mechanistically, Magnoflorine reduces HMGB1 expression in cisplatin-resistant OC cells. Collectively, these results suggest that Magnoflorine has potential as a therapeutic agent for cisplatin-resistant OC in future clinical applications.

查看原文本刊更多论文

magnnoflorine通过下调HMGB1抑制顺铂诱导的保护性自噬，增加耐药卵巢癌细胞的药物敏感性

卵巢癌（OC）是一种常见的妇科恶性肿瘤，为了提高其治疗效果，有必要寻找新的和更有效的治疗药物。木兰花碱是一种基本的氯类生物碱，具有多种药理作用，包括抗糖尿病和抗炎作用。然而，木兰花碱能否通过调节（高迁移率组B1） HMGB1抑制顺铂诱导的保护性自噬还有待进一步研究。本研究旨在评估木兰碱对卵巢癌患者顺铂耐药的影响。我们的研究结果表明，magnnoflorine可以增强OC细胞对顺铂的敏感性。此外，它促进顺铂耐药OC细胞的凋亡，同时抑制顺铂诱导的保护性自噬。在机制上，木兰花碱可降低顺铂耐药OC细胞中HMGB1的表达。总之，这些结果表明木兰花碱在未来的临床应用中有潜力作为顺铂耐药OC的治疗剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of gynaecological oncology 医学-妇产科学

自引率

25.00%

发文量

审稿时长

1 months

期刊介绍： EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.